Inflation Reduction Act is destabilizing investment in drug innovation, execs say

Healthcare Finance News June 16, 2023
Susan Morse

The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says.

The Inflation Reduction Act has the consequence of limiting investment in new drugs at a time when the science is there to innovate, pharma executives said during a call with J.P. Morgan analysts this week.

There are “more targets to go after and more tools to do it,” said David Ricks, chairman and CEO of Eli Lilly. “The problem I see ahead is we don’t have a reliable way to get our drugs to patients in a way that can sustain the innovation we’re talking about. And the IRA fits squarely into that discussion, because it’s a hugely...

Today's Sponsors

Today's Sponsor